News
NONOF
48.64
NaN%
--
Dr. Reddy's falls as quality issue delays supplies of Ozempic generic
Seeking Alpha · 1d ago
Novo Nordisk Loses Its Edge, And I'm Downgrading
Seeking Alpha · 3d ago
Kailera falls after late-stage trial data for oral GLP-1 candidate
Seeking Alpha · 3d ago
Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade
Seeking Alpha · 3d ago
Boston Scientific: The Time Has Come To Catch This Falling Knife
Seeking Alpha · 4d ago
My Top 5 Pharma Stocks Wall Street Ignores
Seeking Alpha · 4d ago
Weekly Report: what happened at NONOF last week (0629-0703)?
Weekly Report · 4d ago
Novo reportedly seeking discounts from suppliers to cut costs
Seeking Alpha · 07/02 13:05
Medicare opens access to GLP-1 weight-loss drugs
Seeking Alpha · 07/01 12:18
Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate
Seeking Alpha · 06/30 18:32
Weekly Report: what happened at NONOF last week (0622-0626)?
Weekly Report · 06/29 09:48
Eli Lilly: Exceptional Pipeline, Less Attractive Entry Point (Rating Downgrade)
Seeking Alpha · 06/26 17:42
Novo Nordisk: 3 Key Reasons The 'Buy The Dip' Thesis Is Flawed
Seeking Alpha · 06/26 16:56
Undercovered Dozen: Blue Owl, IBM, Quantum Computing, Fiserv And More
Seeking Alpha · 06/24 23:13
Novo Nordisk: A Strong Yield And Continued Growth
Seeking Alpha · 06/24 17:59
Novo Nordisk: The Selloff Looks Like A Gift, And I'm Buying
Seeking Alpha · 06/23 12:54
Weekly Report: what happened at NONOF last week (0615-0619)?
Weekly Report · 06/22 09:53
Eli Lilly: Pharma With Unstoppable Momentum Targets Pain With Latest M&A Deal
Seeking Alpha · 06/17 16:58
Novo to soon follow Lilly in seeking Chinese nod for weight-loss pill
Seeking Alpha · 06/17 15:24
Novo Nordisk: A Fallen Leader Trading At Fair Value, Not A Bargain
Seeking Alpha · 06/17 07:39
More
Webull provides a variety of real-time NONOF stock news. You can receive the latest news about Novo-Nordisk A S through multiple platforms. This information may help you make smarter investment decisions.
About NONOF
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.